Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Lung Neoplasms 51Leukemia, Myeloid, Acute 45Neoplasm Metastasis 43Carcinoma, Non-Small-Cell Lung 37Breast Neoplasms 37Prostatic Neoplasms 30Multiple Myeloma 30Colorectal Neoplasms 27Pancreatic Neoplasms 26Melanoma 23Carcinoma, Renal Cell 23Ovarian Neoplasms 21Lymphoma 20Burkitt Lymphoma 19Triple Negative Breast Neoplasms 18Myelodysplastic Syndromes 18Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Large B-Cell, Diffuse 17Urinary Bladder Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Squamous Cell Carcinoma of Head and Neck 14Glioblastoma 14Fallopian Tube Neoplasms 14Carcinoma, Hepatocellular 14Oropharyngeal Neoplasms 13Glioma 13Sarcoma 12Mouth Neoplasms 12Carcinoma 12Astrocytoma 12

Interventions

pembrolizumab 3fludarabine 3aldesleukin 3Cyclophosphamide 3cabozantinib 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2olaparib 1gallium 68 PSMA-11 1enfortumab vedotin 1darolutamide 1Therapeutics 1Radiosurgery 1Radiation Dose Hypofractionation 1Pluvicto 1Mitomycin 1Lutetium-177 1Lutetium 1Loperamide 1Geriatric Assessment 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Fecal Microbiota Transplantation 1Exercise 1Continuous Positive Airway Pressure 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Specimen Handling × 90 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡